In 2017, life sciences organizations will need to find ways to simultaneously manage costs, pricing, and new regulation – all while delivering clinical innovation (1), according to a recent article by Deloitte. The pressures are creating a new normal in this sector and causing disruption in the industry. From the changes in new legislation and regulations to the shift in patient- and customer-centered models, the industry already looks different today than it did just a few years ago.
The changing landscape and pressure for innovation and cost-management is a significant challenge for many life sciences companies. Couple that with the fact that maintaining a competitive advantage requires some degree of capital investment, and suddenly staying afloat amid waves of change becomes increasingly more complex.
There is a way to make capital investments more palatable during a time of uncertainty and transformation: by turning to lease-financing.
As you consider all angles for navigating the new normal of this environment, be cognizant to include a strategy for handling resulting capital investments.
Facing change is complex enough – allow us to help with capital investments along the way. At First American, we are helping life sciences companies achieve their growth goals through creative financing solutions. Visit: http://falifesciences.com/Services/Equipment-Financing
(1) Deloitte. (2017). "The forecast for life sciences in 2017"